常规化疗和靶向抗癌药物的免疫效应。
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
机构信息
Equipe 11 Labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France; INSERM, U1138, 75006 Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, 75006 Paris, France; Université Pierre et Marie Curie/Paris VI, 75006 Paris, France; Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
Equipe 11 Labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France; INSERM, U1138, 75006 Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, 75006 Paris, France; Université Pierre et Marie Curie/Paris VI, 75006 Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
出版信息
Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012.
The tremendous clinical success of checkpoint blockers illustrates the potential of reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in the clinical practice, accumulating evidence indicates that the efficacy of conventional and targeted anticancer agents does not only involve direct cytostatic/cytotoxic effects, but also relies on the (re)activation of tumor-targeting immune responses. Chemotherapy can promote such responses by increasing the immunogenicity of malignant cells, or by inhibiting immunosuppressive circuitries that are established by developing neoplasms. These immunological "side" effects of chemotherapy are desirable, and their in-depth comprehension will facilitate the design of novel combinatorial regimens with improved clinical efficacy.
检查点抑制剂的巨大临床成功表明，重新建立潜在的免疫监视以用于癌症治疗具有巨大潜力。尽管在临床实践中被很大程度上忽视，但越来越多的证据表明，传统和靶向抗癌药物的疗效不仅涉及直接的细胞抑制/细胞毒性作用，还依赖于（重新）激活针对肿瘤的免疫反应。化疗可以通过增加恶性细胞的免疫原性，或者通过抑制肿瘤发展所建立的免疫抑制回路，来促进这种反应。这些化疗的免疫“副作用”是理想的，深入了解这些作用将有助于设计具有改善临床疗效的新型联合方案。
Zotero 插件